Stock Price Forecast

Sept. 8, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Surface Oncology Inc chart...

About the Company

surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww

$-3M

Total Revenue

90

Employees

$65M

Market Capitalization

-0.67

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SURF News

Surface Oncology CEO Rob Ross returns, with new $150M-backed startup

8d ago, source:

The new immuno-oncology company is co-located in Cambridge and Rockville, Maryland, is backed by a $150 million Series A ...

Johns Hopkins cancer treatment spinout launches with $150M, establishes D.C.-area hub

8d ago, source:

A Johns Hopkins University biotech spinout just launched with $150 million to get its cancer treatment into clinical trials — and establish one of two hubs in Greater Washington.

Coherus BioSciences files patent for cancer treatment method using specific antibodies

6d ago, source: Pharmaceutical Technology

Discover a groundbreaking method for treating cancer with Coherus BioSciences Inc.'s patent application. Learn how administering anti-IL-27 antibody, atezolizumab, and bevacizumab can stimulate an ...

2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?

on MSN ago, source:

Shares of Walgreens are down about 79% from the all-time high they reached in 2015. On the surface, Walgreens' 4.7% dividend ...

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

15d ago, source:

Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter ...

UP’s Professor Zodwa Dlamini and Team SAMBAI secure $25M to tackle global cancer Inequities

on MSN ago, source:

A global, interdisciplinary team of researchers, including the University of Pretoria’s (UP) Professor Zodwa Dlamini has been selected to receive a Cancer Grand Challenges award of up to $25m over ...

Lumicell Introduces Further Research and Insights in Fluorescence-Guided Surgery at the Society of Surgical Oncology (SSO) Annual Meeting

3d ago, source:

Lumicell Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer detection ...

The Resilience of Monoclonal Antibodies and their Makers

13d ago, source: The Scientist

The road to developing monoclonal antibodies for effectively targeting cancer was paved with tenacity, passion, and strokes ...

Most detailed atlas to date of human blood stem cells could guide future leukemia care

on MSN ago, source:

Thanks to an unusual application of game theory and machine learning technology, a large team of scientists led by experts at ...

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

1d ago, source:

Revenue for 2023 was $1.1 million, which was generated from the Company’s research collaborations with BioNTech SE and Genentech Inc. This compares with revenue for 2022 of $3.2 million, which was ...

Linkage of Cancer and Lupus in Gliomas Patients

3d ago, source:

Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

1d ago, source:

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...